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Abstract 
Introduction: The management of oral mucositis is a challenge, due to its complex biological nature. Over the last 
10 years, different strategies have been developed for the management of oral mucositis caused by chemotherapy 
in cancer patients. 
Material and Methods: An exhaustive search was made of the PubMed-Medline, Cochrane Library and Scopus 
databases, crossing the key words “oral mucositis”, “prevention” and “treatment” with the terms “chemotherapy” 
and “radiotherapy” by means of the boolean operators “AND” and “NOT”. A total of 268 articles were obtained, 
of which 96 met the inclusion criteria. 
Results: Several interventions for the prevention of oral mucositis, such as oral hygiene protocols, amifostine, ben-
zidamine, calcium phosphate, cryotherapy and iseganan, among others, were found to yield only limited benefits. 
Other studies have reported a decrease in the appearance and severity of mucositis with the use of cytoprotectors 
(sucralfate, oral glutamine, hyaluronic acid), growth factors, topical polyvinylpyrrolidone, and low power laser 
irradiation. 
Conclusions: Very few interventions of confirmed efficacy are available for the management of oral mucositis due 
to chemotherapy. However, according to the reviewed literature, the use of palifermin, cryotherapy and low power 
laser offers benefits, reducing the incidence and severity of oral mucositis – though further studies are needed to 
confirm the results obtained.
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Introduction
The term “mucositis” was introduced in late 1980 to des-
cribe inflammation of the oral mucosa induced by radio-
therapy (observed in 80% of the patients), chemotherapy 
(in 40-80% of the patients) and bone marrow transplanta-
tion (in over 75% of the patients) – the phenomenon being 
regarded as a manifestation of leukopenia (1-3). At pre-
sent, oral mucositis is considered to be the most serious 
non-hematological complication of cancer treatment (3).
-Physiopathology of mucositis
While it is clear that chemotherapeutic agents target 
rapidly dividing healthy tissues, including the oral mu-
cosa and gastrointestinal tract, new studies indicate that 
damage to submucosal components occurs before the 
epithelial lesions become manifest (4,5). Specifically, 
damage and apoptosis of fibroblasts and vascular endo-
thelial cells appear to precede the epithelial lesions. On 
a mechanical basis, endothelial cell damage resulting 
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from the loss of secretion of epithelial growth factors 
such as keratinocyte growth factor (KGF) may explain 
the deregulation of the normal mucosal epithelial growth 
patterns (2,4). Other critical factors leading to ulceration 
include the early release of inflammatory cytokines and 
reactive oxygen species (ROS) at mucosal level. This in 
turn activates transcription factors such as nuclear factor 
kappa B (NF-kB), inducing the over-regulation of spe-
cific genes (tumor necrosis factor, IL-6, and IL-1) and 
triggering apoptosis and the cascade of events leading 
to epithelial ulceration (2,6,7). It is also believed that 
bacterial colonization and/or secondary colonization of 
the ulcers prolongs the corresponding healing times (2). 
However, recent hypotheses and clinical data suggest 
that infection is not a central element in the development 
of mucositis (5-7).
-Risk factors for mucositis
A number of risk factors have been reported to influence 
the frequency and severity of mucositis. Some factors 
are related to the patient, such as the type of tumor in-
volved (hematological diseases)(1-3), age (young pa-
tients)(3), buccodental health (poor oral hygiene before 
and during chemotherapy)(3), the nutritional condition 
of the patient, and the maintenance of kidney and liver 
function. Other factors are related to the type of cytos-
tatic agent used, e.g., drugs that affect DNA synthesis, 
such as antimetabolites (methotrexate, 5-fluorouracil) 
and purine analogs (cytarabine), are associated to inci-
dences of oral mucositis of close to 40-60% (4). Further-
more, methotrexate and etoposide are secreted in saliva, 
which increases their oral toxicity. However, asparagina-
se and carmustine are not related to the development of 
mucositis (2). With regard to combinations of cytostatic 
agents, between 40-70% of all patients receiving stan-
dard chemotherapy regimens develop mucositis (2,3). 
Lastly, the frequency of administration and concomitant 
treatment with radiotherapy and/or bone marrow trans-
plantation are also factors that condition the appearance 
of mucositis (3,4,7).
-Clinical characteristics of mucositis
Mucositis manifests as erythema, edema or ulceration 
that can be accompanied by alterations ranging from mild 
burning sensation to large and painful ulcers that wor-
sen patient quality of life and limit basic oral functions 
such as speech, the swallowing of saliva or eating (2,4). 
Mucositis tends to appear sooner after chemotherapy 
than after radiotherapy, and more often affects the non-
keratinized mucosa (2). Its maximum expression occurs 
7-10 days after chemotherapy, and erythema progresses 
towards ulceration. This is the period of maximum pa-
tient pain and discomfort, and in many cases requires 
the administration of opioids and changes in diet. Mu-
cositis then gradually subsides, leaving no scars, over a 
period of 2-3 weeks after infusion of the drug, provided 
the patient does not present bone marrow suppression. 
The development of infections, caused mainly by herpes 
simplex virus or Candida albicans (though other species 
of Candida, such as krusei tropicalis, parapsilosis and 
glabrata, or other fungal genera such as Aspergillus and 
Mucor, may also be involved), is a serious complication 
observed mainly in patients with prolonged neutropenia, 
and may prove life-threatening (2). Streptococcus oralis 
and Streptococcus mitis are among the most common 
bacteria isolated from blood, and S. mitis can cause adult 
respiratory distress syndrome, particularly when high-
dose cytarabine is administered (2).
-Evaluation
A number of methods have been developed to measure 
and quantify the changes that occur in the oral epithe-
lium. However, the scale most commonly used in re-
search is that developed by the World Health Organiza-
tion (WHO), which combines the clinical characteristics 
of the oral mucosa with the capacity of the patient to eat 
(1-3,5). As regards the clinical evaluation of mucositis, 
the most widely used scale is that forming part the Com-
mon Toxicity Criteria for Adverse Events (CTCAE) of 
the United States National Cancer Institute, which con-
template the patient symptoms, the capacity for oral in-
take, and the need for treatment measures (4).
-Treatment
Although its complex biological nature makes the mana-
gement of oral mucositis a challenge, many strategies are 
used by oncologists to minimize the adverse effects of 
anticancer treatment, including dose reduction and other 
both therapeutic and preventive measures. The present 
study was designed to examine the main treatment op-
tions for oral mucositis due to chemotherapy found in 
the scientific literature.
Material and Methods 
An exhaustive search was made of the PubMed-Me-
dline, Cochrane Library and Scopus databases, cros-
sing the key words “oral mucositis”, “prevention” and 
“treatment” with the terms “chemotherapy” and “radio-
therapy” by means of the boolean operators “AND” and 
“NOT”. We included human studies and review articles 
published in Spanish or English over the last 10 years. 
Opinion articles, series involving fewer than 5 cases, 
and studies using radiotherapy as sole or concomitant 
treatment were excluded. A total of 268 articles were ob-
tained, of which 96 met the inclusion criteria (51 clinical 
trials, 3 cohort studies, 5 cross-sectional studies, 4 case 
series and 33 reviews).
Results
Many strategies are used by oncologists to minimize the 
adverse effects of cancer therapy, including dose reduc-
tion and the prescription of other therapeutic and pre-
ventive options (2,7). An account is provided below of 
the main strategies used for the management of oral mu-
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cositis due to chemotherapy, described in the literature 
over the last 10 years.
-Oral hygiene protocols
Most of the published articles report some benefit from 
the use of oral hygiene protocols for the prevention of 
oral mucositis, since the resulting decrease in micro-
bial presence reduces the risk of secondary infections 
(1,3,5,6). The study published by Hickey et al. (3) in 
patients with testicle cancer compared a group of indi-
viduals who received dental treatment before chemothe-
rapy, along with instructions on oral and dental hygiene, 
versus a group in which no oral hygiene protocol was 
used. A 29% decrease in the prevalence of moderate 
oral mucositis was observed in the former group. Other 
studies have obtained similar results (5-7). Although the 
effects of such measures in preventing mucositis are 
questionable (5-7), most authors suggest that oral hy-
giene protocols (careful brushing and the use of dental 
floss and rinses) can reduce the duration and severity of 
mucositis, as well as contribute to prevent bacterial co-
lonization in the context of mucositis (3,5,6). 
-Antimicrobial agents
Regarding the use of chlorhexidine, the results found in 
the literature are contradictory. Nashwan (8) conducted 
a review of clinical trials using chlorhexidine in pedia-
tric patients scheduled to receive chemotherapy. Of the 
5 studies that met the inclusion criteria, four reported 
an important preventive effect in relation to the deve-
lopment and severity of oral mucositis. However, other 
studies indicate that chlorhexidine is not effective in re-
ducing the severity of mucositis (2,6), and it has even 
been described that rinses with saline solution or bicar-
bonate may be equally effective as well as less costly 
(2,6-8). The systematic review conducted by Potting et al. 
(9) found no beneficial effects of chlorhexidine in com-
parison with rinses in the form of sterile water or physio-
logical saline solution. Similar results were obtained in a 
systematic review published by Worthington et al. (10), 
who disadvised the use of chlorhexidine for the preven-
tion of mucositis, since it was not found to be more effec-
tive than placebo. However, rinses with povidone iodine 
reduced the severity of oral mucositis by 30% compared 
with sterile water rinses (9). In contrast to other antisep-
tics, povidone iodine does not damage the oral mucosa. 
Studies have also been made of iseganan hydrochloride, 
though no significant effects in terms of the prevention 
of mucositis have been recorded (6,7,10). The review pu-
blished by Rubenstein et al. (7) concluded that the use of 
antimicrobial agents for the prevention of oral mucositis 
is not justified, since a degree of benefit could only be 
expected in patients with late stage ulcerative mucositis, 
when the risk of bacterial overinfection is greater.
-Antiinflammatory agents
Benzidamine possesses antiinflammatory, analgesic, 
anesthetic and antimicrobial properties, and has been 
used for both the prevention and treatment of oral muco-
sitis, with contradictory results (2,10,11). Other antiinfla-
mmatory drugs used for the prevention of oral mucositis 
due to chemotherapy are misoprostol rinses, histamine 
in gel format, and the intravenous / intramuscular ad-
ministration of immunoglobulins (11,12). However, the 
study published by Dueñas-Gonzalez et al. (12) recor-
ded an increased incidence and severity of mucositis in 
the group treated with misoprostol in tablets versus the 
placebo group. Another more recent study by Lalla et al. 
(11) likewise recorded no beneficial effect with the use 
of misoprostol in rinses (200 µg in 15 ml of water), in a 
series of 22 patients. Diphenhydramine rinses and mesa-
lazine in gel format have also been studied, and although 
the results of the different publications suggest that such 
products may be effective, further research is needed to 
determine their true efficacy (12). 
-Cytoprotective agents
Amifostine is believed to act by suppressing reactive 
oxygen species (ROS), which play a key role in the etio-
pathogenesis of oral mucositis. However, as a result of 
either methodological deficiencies or the use of a small 
sample size, the different studies have not found ami-
fostine to reduce the duration or severity of mucositis 
induced by chemotherapy (2,6). As described by the li-
terature, another less widely used cytoprotective agent 
with little impact upon the management of oral muco-
sitis due to chemotherapy is sucralfate – the side effects 
of which include nausea and other gastrointestinal di-
sorders such as rectal bleeding (5,6). Another sugges-
ted treatment is the topical application of prostaglandins 
E1 (misoprostol) and E2 (used to protect the digestive 
mucosa), with contradictory results (2,10,11). Vitamin 
E (α-tocopherol) is an antioxidant that can limit ROS-
mediated tissue damage, and thus lessen the severity of 
mucositis during cancer therapy (2,3,13). El-Housseiny 
et al. (13) evaluated the effect of topical versus systemic 
vitamin E in patients with oral mucositis due to chemo-
therapy, and concluded that the topical application of 
100 mg of vitamin E twice a day results in disappearan-
ce of the mucositis lesions. However, Sung et al. (14) 
did not find the prophylactic use of vitamin E to lessen 
the appearance of oral mucositis in children treated with 
doxorubicin. Further studies are needed, since this subs-
tance has been shown to be effective in treating esta-
blished lesions, but does not prevent the development 
of new lesions (3,13,14). Glutamine has been used for 
both the prevention and treatment of mucositis, adminis-
tered via the oral route, as rinses, and via the enteral and 
intravenous routes. One of the studies included in the 
review published by Rubenstein et al. (7) examined the 
effect of glutamine administered via the parenteral route 
in 24 patients with metastatic colorectal cancer treated 
with 5-fluorouracil, and recorded a significant decrease 
in mucositis and gastric ulcerations in the group of pa-
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tients administered glutamine versus placebo (p<0.01). 
However, other authors have obtained contradictory re-
sults, including Pytlik et al. (15), who not only found 
glutamine to be ineffective in preventing mucositis but 
also suggested that the drug could worsen mucositis and 
even increase the risk of tumor relapse. The randomi-
zed, double-blind, controlled multicenter phase III cli-
nical trial carried out by Peterson et al. (16) in breast 
cancer patients subjected to chemotherapy examined the 
efficacy of Saforis® (oral glutamine) at a dose of 2.5 g/5 
ml administered three times a day versus placebo, and 
recorded a significant decrease in the incidence and se-
verity of oral mucositis in the patients treated with Safo-
ris®. Another drug used for the prevention of mucositis 
is irsogladine maleate, which is not marketed in Spain. 
Only one study is found in the literature, involving the 
administration of 4 mg/day of irsogladine via the oral 
route during 14 days from the first day of the chemo-
therapy cycle in patients treated with 5-fluorouracil. The 
drug was seen to significantly reduce the incidence of 
oral mucositis versus the control group (17).
-Biological response modifiers
In the treatment of cancer, growth factors are indicated 
for reducing the duration of neutropenia in patients with 
non-myeloid malignancies subjected to chemotherapy, 
and for accelerating myeloid recovery in patients sub-
jected to bone marrow transplantation. Many studies, 
mostly published before the year 2004 (thus causing 
us to conduct an independent search), have found that 
rinses containing granulocyte colony-stimulating factor 
(G-CSF) and granulocyte macrophage colony-stimula-
ting factor (GM-CSF) may significantly reduce the dura-
tion and severity of mucositis (18-23). In this regard, in 
the study of Crawford et al. published in 1999 (18), in-
volving patients diagnosed with lung cancer and treated 
with cyclophosphamide, etoposide and doxorubicin, the 
percentage of patients who developed oral mucositis was 
seen to be lower in the group treated with subcutaneous 
G-CSF than in the control group (53% versus 70%, res-
pectively). The study published by Katano in 1995 (19), 
involving G-CSF via the subcutaneous route, and the 
article published by Karthaus in 1998 (20) with G-CSF 
rinses, have obtained similar results. However, the ran-
domized, controlled clinical trial carried out by Patte et 
al. in 2002 (24) did not find the administration of G-CSF 
via the subcutaneous route to be effective in preventing 
oral mucositis. Regarding the use of GM-CSF, the study 
published by Chi et al. in 1995 (23) found the systemic 
administration of GM-CSF in patients with head and 
neck cancer subjected to chemotherapy (5-fluorouracil 
and cisplatin) to reduce the severity and duration of oral 
mucositis. Similar data have been obtained by other 
studies with the use of GM-CSF rinses, with reduction 
of the severity, morbidity and duration of oral mucosi-
tis induced by chemotherapy (Ibrahim in 1997 (21) and 
Hejna in 2001 (22)). However, Cartee et al. in 1995 (25) 
did not find rinses containing GM-CSF to reduce the 
appearance of oral mucositis in patients with breast can-
cer subjected to chemotherapy (5-fluorouracil, adriamy-
cin and methotrexate). Palifermin is a human truncated 
recombinant form of keratinocyte growth factor (KGF) 
produced by recombinant DNA technology in Escheri-
chia coli. It is indicated in patients with hematological 
malignancies subjected to myeloablative therapy, which 
is associated to a high incidence of severe mucositis, sin-
ce the drug stimulates epithelial cell proliferation and 
increases the thickness of the non-keratinized layers 
of the oral and gastrointestinal mucosa – thereby redu-
cing the incidence, duration and severity of mucositis. 
Palifermin is administered via the intravenous route at 
a dose of 60 µg/kg/day during three consecutive days 
before and after myelosuppressive therapy, for a total of 
6 doses. The third dose is administered 24-48 hours be-
fore bone marrow suppression (2,10,26). According to 
the reviewed literature, the administration of palifermin 
at doses between 1-180 µg/kg/day reduces the inciden-
ce and severity of oral mucositis (Table 1) (26-30). The 
most frequent adverse reactions affect particularly the 
skin and oral mucosa, with dysgeusia, paresthesia, hy-
pertrophy of the oral mucosa and tongue papillae, color 
changes of the oral mucosa, rash, pruritus, erythema and 
hyperpigmentation of the skin, among other alterations 
(26,30). Other undesirable effects include cough, rhini-
tis and arthralgia. These problems are usually mild or 
moderate in intensity, appear in the last three days of 
treatment, and according to some studies do not require 
interruption of the drug (2,6,26,30).
-Physical therapies (cryotherapy and laser)
The topical application of ice (cryotherapy) on the oral 
mucosa has been shown to offer benefit in the preven-
tion of oral mucositis in some patients receiving chemo-
therapy. The precise underlying mechanism is not clear, 
though as mentioned by Mahood et al., cryotherapy is 
believed to induce local vasoconstriction – thereby re-
ducing oral mucosal blood flow and exposure of the mu-
cosa to the cytostatic agent, with a consequent decrease 
in direct toxicity (2). Since the half-life of 5-fluorouracil 
is short (5-20 minutes), different studies have found that 
the application of cryotherapy during 5-10 minutes befo-
re administration of the drug, 15-35 minutes during ad-
ministration, and up to 30 minutes after administration, 
significantly reduces mucositis (31-39). Studies have 
also been made in patients administered conditioning 
treatment with high-dose melphalan, with good results 
(35,36). However, the results obtained in patients admi-
nistered other cytostatics such as methotrexate, etoposi-
de, cisplatin, mitomycin, edatrexate and vinblastine are 
inconclusive (6,36,37,39) (Table 2). Furthermore, cryo-
therapy is not indicated in patients treated with certain 
chemotherapeutic agents such as oxaliplatin, since acute 
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
AUTHOR P/T N MA 
(range) 
GROUPS (N) ADMINISTRATION OBSERVATIONS 
Meropol et al. (2003) P 81 63 
(41-86) 
SG: KGF in boluses of 1, 10, 
20, 40, 60 and 80 µg/kg/day 
(7, 8, 10, 11, 8, 10=54) 
CG: placebo (27) 
Three days before CT Ļ Severe OM at dose 10 
µg/kg/day (++ at dose > 20 
µg) 
Ĺ Mild-moderate adverse 
effects at dose 20 µg/kg/day 
(onset 36 h after first dose of 
KGF and resolution in 7-10 
days) 
Horsley et al. (2007) P 59 56.65 SG: palifermin i.v. 60 
µg/kg/day (32) 
CG: standard treatment (27) 
Three days before CT and 
3 days after SCT 
Ļ Incidence of severe OM 
Ļ Swallowing difficulties 
Ļ Days of admission 
Schmidt et al. (2008) P 10 ND SG: palifermin i.v. in doses 
of 30-40-60 µg/kg/day (10) 
CG: first cycle of CT, no 
prophylaxis (10) 
*the patients act as their own 
controls; SG comprises the 
10 patients with severe OM 
after first cycle of CT in 
absence of prophylaxis with 
palifermin (CG) 
Three days before CT and 
3 days after 
Ļ Duration and intensity of 
severe OM in patients treated 
with high-dose methotrexate 
Ļ Clinical complications such 
as infection 
Ļ Use of opioid analgesics i.v. 
Ayago Flores et al. (2010) P 36 54.5 
(18-70) 
SG: palifermin i.v. 60 
µg/kg/day (11) 
CG: mepivacaine rinse 2%, 
dexamethasone and 
chlorhexidine 0.05% (25) 
Three consecutive days 24-
48 hours pre-CT and days 
0, 1, 2 post-transplant 
Ļ Duration of OM, mean 
duration 5 days 
• No significant differences in 
incidence of OM, sepsis or 
febrile neutropenia, 
administration of opiates or 
use of parenteral nutrition 
 
Vadhan-Raj et al. (2010) P 48 45 
(15-64) 
SG: palifermin i.v. 180 µg/kg 
(32) 
CG: placebo i.v. (16) 
 
Single dose: 3 days before 
each cycle of CT 
Ļ Incidence and severity of 
OM in SG 
Ļ Duration of OM, mean 
duration 4.5 days in SG 
• Mucosal thickening in 72% 
of patients in SG 
Table 1. Use of palifermin in the management of oral mucositis (26-30). P/T: prevention / treatment of oral mucositis; N: number of patients; EM: 
mean age in years; ND: not declared; SG: study group; CG: control group; i.v.: intravenous; CT: chemotherapy; SCT: stem cell transplantation; 
OM: oral mucositis; KGF: keratinocyte growth factor-palifermin. 
neurological manifestations may develop in the form of 
mandibular stiffness and laryngopharyngeal dysesthesia 
(6). Phototherapy with low power laser has also been 
used for both the prevention (10) and treatment of oral 
mucositis due to chemotherapy (38,40-43). Different 
studies have described a decrease in the incidence and 
severity of mucositis, apparently due to acceleration of 
affected tissue regeneration and healing, thereby redu-
cing the inflammation and pain (10,38). A number of au-
thors support the use of low power laser for preventing 
oral mucositis in patients subjected to hematopoietic 
stem cell transplantation and scheduled for high-dose 
chemotherapy (with or without total body irradiation)
(10,38,40-44). However, the clinical trial carried out by 
Cruz et al. (44) in pediatric patients yielded no evidence 
that the use of low power laser affords increased benefits 
(Table 3).
-Anesthetics and analgesics (management of pain)
Although no drug has been shown to successfully eli-
minate mucositis, the management of the pain symp-
toms with anesthetic solutions (diphenhydramine, vis-
cous xylocaine and lidocaine) and potent analgesics 
such as morphine rinses, the application of sublingual 
methadone or fentanyl patches, could afford relief from 
the oral discomfort and improve patient quality of life 
(6,7,10,38). A so-called “magic mouthwash” has been 
described, containing variable amounts of diphenhydra-
mine, viscous lidocaine, bismuth subsalicylate and cor-
ticosteroids, with the purpose of affording pain relief 
and lessening the inflammation. However, some studies 
have not recorded significant improvement of the pain 
(6,7,10,38). The application of capsaicin and the use of 
colchicine rinses have also been described as treatments 
for pain associated to mucositis (6,38). According to the 
review published by Worthington et al. (10), there is no 
evidence that patient controlled analgesia is better than 
continuous infusion, although less opioid is administe-
red per hour and the duration of pain is shorter. Never-
theless, different studies recommend patient controlled 
analgesia in place of continuous infusion or administra-
tion supervised by the nursing personnel (7,10,38).
-Other agents
Allopurinol administered in rinses, pieces of ice or via 
the systemic route has been studied for the prevention of 
mucositis in patients receiving chemotherapy with 5-fluo-
rouracil or methotrexate, though the results obtained are 
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AUTHOR (year) MATERIAL 
USED 
P/T N EM 
(range) 
CHARACTERISTICS: 
wavelength, power, 
energy density, power 
density, energy/point, 
size (N) 
ADMINISTRATION OBSERVATIONS 
Nes et al. (2005) Diode laser 
(AsGaAl) 
T 13 38-76 830 nm, 250 mW, 35 
J/cm2, 0.60 mm pointer 
size 
From diagnosis of OM 
and during 5 days 
Ļ Pain (immediate) 
Cruz et al. (2007) Diode laser 
(GaAlAs) 
P 60 8.7±4.3 
(3-18) 
SG: laser 780 nm, 60 
mW, 4 J/cm2 (29) 
CG: no laser (31) 
During first 5 days post-
CT 
• No evidence of laser 
preventive effect upon 
OM in pat. with good oral 
hygiene 
Abramoff et al. 
(2008) 
Diode laser 
(AsGaAl) 
P and T 13 14.6 
(7-23) 
G1: prophylactic laser 
absence OM (7 pat., 11 
cycles) 
G2: placebo light absence 
OM 
(7 pat., 11 cycles) 
G3: therapeutic laser 
presence OM (6 pat., 10 
cycles). 
Laser characteristics: 685 
nm, 35 mW, 72 J/cm2, 2 J, 
0.06 cm2 (54 sec.) 
G1 and G2: in first 24 h 
of start of CT, after 2 
days and on day 4 
G3: at diagnosis of OM, 
after 2 days and on day 
4 
• Prophylactic laser: Ļ 
incidence OM 
• Therapeutic laser: Ļ 
severity OM, even in pat. 
with severe 
granulocytopenia 
• Underscore laser use in 
pediatric pat. due to: 
x Easy use 
x Ĺ acceptance by 
patients 
x Ļ pain 
Kuhn et al. (2009) Diode laser 
(GaAIAs) 
T 21 8.2±3.1 
(ND) 
SG: laser 830 nm, 100 
mW, 4 J/cm2 (9) 
CG: placebo light (12) 
From diagnosis of OM 
and during 5 days 
Ļ Duration of OM 
• Good treatment 
alternative in pediatric 
pat. 
Freitas et al. (2014) LED and laser 
phototherapy 
(InGaAlP) 
T 40 53.95 
(ND) 
G1: 630 nm, 80 mW, 0.24 
J/cm2, 0.08 W/cm2, 0.24 
J, 1 cm2 (3 sec./point)(17) 
G2: 660 nm, 40 mW, 6.6 
J/cm2, 1.1 W/cm2, 0.24 J, 
0.036 cm2 (6 
sec./point)(23) 
Post-CT during 10 
consecutive days except 
weekends 
• LED therapy more 
effective than 
phototherapy: Ļ pain and 
severity of OM 

Table 3. Use of laser therapy in the management of oral mucositis (40-44). P/T: prevention / treatment of oral mucositis; N: number of patients; 
EM: mean age in years; ND: not declared; pat.: patient; G: group; SG; study group; CG: control group; CT: chemotherapy; OM: oral mucositis. 
*This study is divided into two clinical trials; reference here is to the first trial, since the second included patients that received radiotherapy.
inconclusive (6,10,12,38). On the other hand, propanthe-
line reduces salivation and may thus lessen oral mucosal 
exposure to chemotherapeutic agents that are excreted 
in saliva (2). According to some publications involving 
small sample sizes and with shortcomings in terms of 
design, propantheline can reduce mucositis associated to 
the administration of etoposide or the combination of di-
fferent chemotherapeutic agents (ifosfamide, carbopla-
tin and etoposide) in patients subjected to autologous he-
matopoietic stem cell transplantation (2). Some studies 
advocate the use of Caphosol® rinses for the prevention 
and treatment of mucositis (10,38,45). These rinses are 
composed of two aqueous electrolytic solutions in sepa-
rate containers - a phosphate solution (Caphosol A) and 
a calcium solution (Caphosol B) - which when combined 
in equal volumes form an oversaturated solution of cal-
cium and phosphate ions that humidify and lubricate the 
oral mucosa. Waśko-Grabowska et al. (45) found the ad-
ministration of Caphosol® rinses to reduce the inciden-
ce, severity and duration of mucositis in patients treated 
with BEAM regimens (carmustine, cytarabine, etoposi-
de and melphalan), in contrast to the group treated with 
melphalan 200. Arbabi-kalati et al. (46) administered 
220 mg of zinc sulfate daily in capsule form to patients 
receiving chemotherapy, and observed a decrease in the 
intensity of mucositis. However, the incidence in the 
control group was similar. Some studies have examined 
the usefulness of honey and propolis in the management 
of mucositis, in view of their antibacterial and regene-
rative properties. Although further research is needed, 
involving a larger number of patients (6,7,10,38), honey 
may be a valid alternative for improving the symptoms 
and shortening the duration of mucositis.
Discussion
The management of oral mucositis is a challenge, due 
to its complex biological nature (2,5,6,10,38). Although 
the scientific literature describes a number of manage-
ment strategies, the data available to date are heteroge-
neous and inconclusive (5,10,38).
The Cochrane Library has published a series of reviews 
on the prevention of oral mucositis produced by radio-
therapy and/or chemotherapy (2000, 2003, 2006, 2007, 
2010 and 2011). The latest update conducted by Wor-
thington et al. (10) concluded that only 10 interventions 
(aloe vera, amifostine, cryotherapy, granulocyte colony-
stimulating factor (G-CSF), intravenous glutamine, ho-
ney, keratinocyte growth factor, laser irradiation, po-
lymyxin / tobramycin / amphotericin (PTA) antibiotic 
tablet / paste, and sucralfate) offer some benefit in terms 
of the prevention or reduction of mucositis associated 
to cancer therapy. Of these 10 interventions, cryothera-
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py, palifermin and sucralfate showed statistically signi-
ficant benefit in preventing or reducing the severity of 
mucositis. It should be noted that the use of cryotherapy 
was exclusively investigated in patients with hematolo-
gical malignancies subjected to chemotherapy or stem 
cell transplantation; palifermin in patients subjected to 
radiotherapy, stem cell transplantation, chemotherapy 
or a combination of these treatments; and sucralfate in 
patients subjected to radiotherapy.
Since it is safe, inexpensive and generally well tolerated, 
cryotherapy is one of the most commonly used interven-
tions for the prevention of oral mucositis, particularly in 
patients receiving treatment with short half-life chemo-
therapeutic agents such as 5-fluorouracil, edatrexate and 
melphalan (3-5,10,31-38). Different studies in patients 
treated with 5-fluorouracil have shown that the adminis-
tration of cryotherapy 5-30 minutes before and for 20-30 
minutes (even up to 6 hours, according to some studies) 
after the 5-fluorouracil bolus dose significantly reduces 
oral mucositis (31-38). The latest update on the guides 
developed by the mucositis study group of the Multi-
national Association of Supportive Care in Cancer and 
the International Society of Oral Oncology (MASCC/
ISOO), published in 2014, recommend the use of cryo-
therapy in patients administered 5-fluorouracil in bolus 
form, and suggest its use in patients treated with high-
dose melphalan as conditioning therapy for hematopoie-
tic stem cell transplantation - independently of whether 
total body irradiation is used or not (5). However, due to 
the lack of evidence in the reviewed studies, it has not 
been possible to establish guidelines for patients recei-
ving other chemotherapeutic agents (5).
At present, the recommendations of different clinical 
guides include prophylaxis with palifermin, in order to 
reduce the incidence and duration of mucositis in patients 
with hematological malignancies subjected to hemato-
poietic stem cell transplantation and prior myeloablative 
therapy, only when the latter includes high doses of che-
motherapy and total body irradiation (5-7,38). However, 
there are also standard chemotherapy regimens that do 
not require stem cell support, which can be associated 
to severe mucositis. Nevertheless, the high cost of pali-
fermin and the efficacy data published to date advise the 
conduction of studies involving larger patient samples, 
in order to establish the impact of palifermin upon other 
variables such as the incidence of mucositis, sepsis or 
febrile neutropenia. Likewise, pharmacoeconomic stu-
dies are needed to facilitate decision making in selecting 
efficient preventive treatment for mucositis (28).
The literature contains a number of studies that have eva-
luated the effects of laser therapy in patients receiving che-
motherapy, with encouraging results (39-43), in contrast to 
the study published by Cruz et al. (44). The MASCC/ISOO 
clinical guide published in 2014 recommends treatment 
with laser involving specific characteristics (wavelength 
about 650 nm, power setting 40 mW, and treatment of each 
square centimeter during the required period of time at a 
tissue energy dose of 2 J/cm2) for the prevention of oral 
mucositis in patients receiving high-dose chemotherapy for 
hematopoietic stem cell transplantation with or without to-
tal body irradiation (5). In addition, research is needed to 
clarify the biological mechanism whereby laser irradiation 
is able to improve healing and lessen pain (38).
The literature describes a number of interventions for 
the prevention and treatment of oral mucositis. Howe-
ver, although there is evidence recommending the use of 
certain treatments, none of them have been clinically va-
lidated, and there is no gold standard for managing mu-
cositis (6). Additional methodologically sound clinical 
trials with a sufficient number of patients are therefore 
needed in order to allow adequate analyses of subgroups 
according to the type of disease and the chemothera-
peutic agent involved (5,38). Such trials in turn should 
be reported following the recommendations of the Con-
solidated Standard of Reporting Trials (CONSORT). 
Furthermore, as indicated by Worthington et al. (10), it 
would be useful for investigators to use a simple muco-
sitis scale (scored from 0-4), such as those developed 
by the World Health Organization (WHO), the Radia-
tion Therapy Oncology Group (RTOG), or the National 
Cancer Institute-Common Toxicity Criteria (INC-CTC), 
in order to facilitate comparison among the different in-
terventions used in application to mucositis.
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